(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Bellmunt provided an updated analysis from the DANUBE trial, evaluating PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC). The DANUBE trial was an open-label, phase III trial including patients with previously untreated mUC. The study did not meet its co-primary endpoints; however, numerically longer survival was observed in pts with high tumour PD-L1 expression who were treated with D or D+T compared with standard of care chemotherapy (SoC).